Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NV-5138 in Healthy Volunteers and TRD
NCT03606395Phase 1Completed
- Sponsor
- Navitor Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mefluleucine in treatment-resistant depression (TRD) (2 arms), sponsored by Navitor Pharmaceuticals. Primary endpoint: Incidence of treatment-related adverse events at Day 9. Started Jun 2018; status: completed.
02
Drugs
mefluleucine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT03606395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03606395.